

ASX ANNOUNCEMENT

Results of Extraordinary General Meeting

22nd April 2016: Analytica Ltd (ASX: ALT) advises that all resolutions were passed by a show of hands.

Proxy votes received were as follows:

Resolution	For	Open votes (Chairman nominated as proxy)	Total Votes For the resolution	Against
1. Approval for issue of Dr Monsour Placement shares	424,301,670 97.4%	7,629,195 1.7%	413,930,865 99.1%	3,828,112 0.9%
2. Ratification of general placement	522,607,168 97.8%	7,629,195 1.4%	530,236,363 99.2%	4,120,759 0.8%
3. Cancellation of options to Salesforce4hire LLC	612,088,700 98.0%	12,331,921 1.9%	624,420,621 99.9%	30,000 0.1%

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA by prescription.

